Preparat złożony atorwastatyna/perindopril — nowoczesna prewencja zdarzeń sercowo-naczyniowych

Abstract

Cardiovascular diseases are the leading cause of death in Poland. The most common cardiovascular risk factors are dyslipidemia and hypertension. Unfortunately, the percentage of patients with well-controlled dyslipidemia and hypertension remains very low. This is mainly due to insufficient statin therapy. Perindopril and atorvastatin are substances with a documented efficacy in reducing the incidence of cardiovascular events. The use of these drugs in one capsule can cause a significant increase in the percentage of patients properly treated and reaching the target values of blood pressure and LDL-cholesterol.